Categories AlphaGraphs, Earnings, Health Care

Earnings preview: Amarin likely to deliver strong Q4 results

Amarin Corporation (AMRN) is scheduled to report earnings results for the fourth quarter of 2018 on Wednesday, February 27, before the market opens. Analysts expect the company to report a loss of $0.08 per share on revenues of $74.4 million for the recently ended quarter.

Amarin has a mixed track record in terms of meeting earnings estimates and over the past four quarters, the company has missed expectations twice. The company’s primary product, Vascepa, has grown consistently over the past nine months and this momentum will continue in the fourth quarter as well. New approvals might also help in driving sales growth going forward.

In November, Amarin published positive results pertaining to the REDUCE-IT study, which evaluated the cardiovascular risk reduction potential of Vascepa, thereby giving the company potential for significant benefits through the affordably-priced drug. However, higher costs are likely to hurt Amarin in the fourth quarter as the company continues to implement strategic initiatives for business growth.

amarin fourth quarter 2018 earnings preview

Last month, Amarin published preliminary results for 2018 and provided its outlook for 2019. The company expects record revenues for the fourth quarter and full year of 2018 in the ranges of $72 million to $76 million and $224 million to 228 million, respectively. The full-year results represent an increase of 24-26% over 2017.

The quarterly and full-year revenue numbers predominantly reflect US sales driven by increased prescriptions for Vascepa. For 2019, Amarin expects total revenue of about $350 million, reflecting an increase of more than 50% from 2018, mostly from US sales of Vascepa.

Amarin’s stock gained 14% on Friday on rumors that Novartis (NVS) might be interested in an acquisition. However, Novartis declined to offer any comment on the issue. Similarly, last month, Amarin’s stock surged on rumors that Pfizer (PFE) was looking to acquire the company. There have been no further reports on the outcome of this matter.

The majority of analysts have rated Amarin as a Strong Buy while none have rated it Sell. Over the past six months, the stock has gained 588% while over the past month, it has climbed 7%. The stock was down 3.6% in morning hours on Monday.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Citigroup (C) reports higher revenue and profit for Q2 2024; earnings beat

Banking behemoth Citigroup Inc. (NYSE: C) Friday reported an increase in revenue and net income for the second quarter of 2024. Earnings came in above analysts’ estimates. Net profit for

Wells Fargo (WFC) Q2 2024 Earnings: Key financials and quarterly highlights

Wells Fargo & Company (NYSE: WFC) reported its second quarter 2024 earnings results today. Total revenue rose 1% year-over-year to $20.7 billion. Net income dropped 1% to $4.9 billion while

JPM Earnings: All you need to know about JPMorgan’s Q2 2024 earnings results

JPMorgan Chase & Co. (NYSE: JPM) reported second quarter 2024 earnings results today. Reported revenue increased 22% year-over-year to $50.2 billion. Managed revenue rose 20% to $51 billion. Net income

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top